- Faron Pharmaceuticals Oy said final results from a study of its interferon-beta drug had shed some light on the lack of clinical response to the drug in a previous trail.

The YODA study was set out to further investigate the findings of the phase III INTEREST study, which had indicated significant reduction of interferon-beta action by steroids, failing to deliver the expected results.

Parts I and II of the YODA study, as previously announced, confirmed that the INTEREST study drug produced the expected levels of bioactivity, suggesting that drug formulation was not a factor in the outcome of the trial and this observation was confirmed during part III of the YODA trial, the company said.

'These YODA results once again are consistent with the INTEREST data, supporting the conclusion that co-administration of steroids with Traumakine in patients inhibited interferon beta action' said Dr Markku Jalkanen, the chief executive officer of Faron.

'The YODA report will become an essential part of our communication dossier with the FDA [US Food and Drug Administration] and EMA [European Medicines Agency] when we justify our clinical double-dummy design for the concomitant use of steroids for the next Traumakine studies.'

The company also said it currently expected to receive the INFORAAA interim results in the near future, allowing full review of all data for its interferon-beta drug Traumakine.

The company currently envisaged that a further Traumakine trial was likely to be funded through third party funding.

At 8:24am: [LON:FARN] Faron Pharmaceuticals share price was +14.5p at 140.5p

Story provided by